Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617 | Director | April 04, 2025 | April 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anebulo Pharmaceuticals, Inc.
Report date April 04, 2025 · Filed April 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03 | Direct | 25,000 |
Reported balance
After 2025-04-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-04 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03 | Direct | 6,618 |
Reported balance
After 2025-04-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-04 · Grant · Acquired 6,618 · Balance 6,618 F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2025 Filed Apr 8, 2025 01:41 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 6,618 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001641172-25-003089 · ownership.xml · derivative · entry 2 SHAH BIMAL R. · CIK 0001557394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,618 Underlying: Common Stock · 6,618 shares Expires 2035-04-03 F1 · derivative.exercise_date: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 01:41 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001641172-25-003089 · ownership.xml · derivative · entry 1 SHAH BIMAL R. · CIK 0001557394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-04-03 F1 · derivative.exercise_date: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:23 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 3,309 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001493152-24-024122 · ownership.xml · derivative · entry 2 SHAH BIMAL R. · CIK 0001557394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,309 Underlying: Common Stock · 3,309 shares Expires 2034-06-12 F2 · derivative.exercise_date: These stock options vest on the earlier of November 30,2024 or the date of the 2024 annual meeting of shareholders Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:23 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 41,667 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001493152-24-024122 · ownership.xml · derivative · entry 1 SHAH BIMAL R. · CIK 0001557394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Stock · 41,667 shares Expires 2034-06-12 F1 · derivative.exercise_date: These stock options vest 50% on the date of the 2024 annual meeting of shareholders and 50% on the one year anniversary of the date of grant Read SEC document |
| October 06, 2023 Filed Oct 11, 2023 01:49 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 26,097 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001209191-23-052586 · doc4.xml · derivative · entry 1 SHAH BIMAL R. · CIK 0001557394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,097 Underlying: Common Stock · 26,097 shares Expires 2033-10-05 F1 · derivative.exercise_date: 25% of the original number of shares vest on the first anniversary of October 6, 2023 (the "Vesting Commencement Date") and 2.0833% of the original number of shares vest at the end of each successive month following the first anniversary of the Vesting Commencement Date until the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.